相关临床试验
29
6 进行中
药物批准
3
批准总数
监管机构
1
监管机构数
成立时间
1976
进行中（未招募）
6
20.7%
已完成
21
72.4%
招募中
1
3.5%
撤回
1
3.5%
- The FDA has approved Obagi saypha ChIQ, an injectable hyaluronic acid gel for cheek augmentation and correction of midface contour deficiencies in patients over 21. - The product utilizes proprietary MACRO Core Technology to create a stable 3D HA matrix designed for natural-looking results with predictable injection force and swelling profiles. - Interim data from the ALOHA Program shows 94% of injectors believe the previously launched Obagi saypha MagIQ complements their current filler options. - The approval strengthens Waldencast's Obagi Medical brand strategy to become a comprehensive leader at the intersection of advanced skincare and medical aesthetics.
- Obagi Medical has launched the ALOHA Program to conduct what is expected to become the largest real-world evaluation of a newly launched hyaluronic acid injectable filler. - The program will systematically collect data from diverse aesthetic practices using Obagi saypha MagIQ, the company's first FDA-approved injectable hyaluronic acid filler. - Alpha Aesthetic Partners has been selected as the first launch partner, conducting structured multi-site evaluations across its network of 31 locations in 12 states. - The initiative aims to bridge the gap between controlled clinical trials and everyday practice conditions by capturing real-world insights on clinical performance and patient experience.
- Obagi Medical presented pivotal clinical data at the 2025 American Society for Dermatologic Surgery Annual Meeting, with their hyaluronic acid filler study selected as a top 10 abstract for oral presentation. - The randomized, multicenter trial demonstrated non-inferiority of Obagi saypha ChIQ compared to Juvederm Voluma XC for midface volume restoration and nasolabial fold improvement. - Additional data included interim three-month results for Nu-Cil BioStim Scalp Serum showing improvements in scalp health and hair appearance. - Obagi saypha ChIQ is currently under FDA review, while the company's saypha MagIQ recently received FDA approval.
- The FDA has approved Obagi saypha MagIQ, an injectable hyaluronic acid gel developed by Croma-Pharma and distributed under the Obagi Medical brand, marking Waldencast's first entry into the US dermal filler market. - The product utilizes proprietary MACRO Core Technology to create a stable 3D HA matrix designed for consistent gel distribution, predictable injection force, and natural-looking results across all skin types. - A pivotal 270-patient clinical trial demonstrated non-inferiority to control fillers with similar safety profiles, including the highest representation of diverse Fitzpatrick skin types in HA filler studies. - Waldencast plans to launch the product in 2026, projecting that this approval will double Obagi Medical's total addressable market to approximately $4.2 billion by 2029.
